The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: A retrospective analysis.
Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI.
Pediatric Rheumatology Online Journal.
2020;
18.
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.
Brunner, HI; Tzaribachev, N; Cornejo, GV; Joos, R; Gervais, E; Cimaz, R; Calvo Penades, I; Cuttica, R; Lutz, T; Quartier, P; et al.
Pediatric Rheumatology Online Journal.
2020;
18.
Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: Analysis by the Pharmachild Safety Adjudication Committee.
Giancane, G; Swart, JF; Castagnola, E; Groll, AH; Horneff, G; Huppertz, H; Lovell, DJ; Wolfs, T; Herlin, T; Dolezalova, P; et al.
Arthritis Research and Therapy.
2020;
22.
Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: A cross-sectional study.
Simon, TA; Harikrishnan, GP; Kawabata, H; Singhal, S; Brunner, HI; Lovell, DJ.
Pediatric Rheumatology Online Journal.
2020;
18.
Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
Brunner, HI; Quartier, P; Alexeeva, E; Constantin, T; Koné-Paut, I; Marzan, K; Schneider, R; Wulffraat, NM; Chasnyk, V; Tirosh, I; et al.
Arthritis and Rheumatology.
2020;
72:2147-2158.
Assessment and treatment of down syndrome-associated arthritis: A survey of pediatric rheumatologists.
Nicek, A; Talib, N; Lovell, D; Smith, C; Becker, ML; Jones, JT.
Pediatric Rheumatology Online Journal.
2020;
18.
Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis.
Brunner, HI; Wong, R; Nys, M; Kou, TD; Dominique, A; Martini, A; Lovell, DJ; Ruperto, N.
Pediatric Drugs.
2020;
22:653-672.
Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results.
Brunner, HI; Nanda, K; Toth, M; Foeldvari, I; Bohnsack, J; Milojevic, D; Rabinovich, CE; Kingsbury, DJ; Marzan, K; Chalom, E; et al.
Arthritis Care and Research.
2020;
72:1420-1430.
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial.
Brunner, HI; Abud-Mendoza, C; Viola, DO; Calvo Penades, I; Levy, D; Anton, J; Calderon, JE; Chasnyk, VG; Ferrandiz, MA; Keltsev, V; et al.
Annals of the Rheumatic Diseases.
2020;
79:1340-1348.
Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell, DJ; Brunner, HI; Reiff, AO; Jung, L; Jarosova, K; Nemcova, D; Mouy, R; Sandborg, C; Bohnsack, JF; Elewaut, D; et al.
RMD Open.
2020;
6:e001208-e001208.